Valuation: MannKind Corporation

Market Cap 1.25B 1.09B 1.01B 928M 1.75B 120B 1.79B 12.03B 4.73B 58.87B 4.69B 4.58B 203B P/E 2026 *
-141x
P/E 2027 * 28.6x
Enterprise Value 1.25B 1.09B 1.01B 928M 1.75B 120B 1.79B 12.03B 4.73B 58.87B 4.69B 4.58B 203B EV / Sales 2026 *
2.7x
EV / Sales 2027 * 2.39x
Free-Float
98.45%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: MannKind Corporation

1 day-0.25%
1 week-2.66%
Current month-5.40%
1 month+4.13%
3 months+46.55%
6 months-22.65%
Current year-28.92%
1 week 3.85
Extreme 3.85
4.2
1 month 3.77
Extreme 3.77
4.55
Current year 2.23
Extreme 2.23
6.51
1 year 2.23
Extreme 2.23
6.51
3 years 2.23
Extreme 2.23
7.63
5 years 2.23
Extreme 2.23
7.63
10 years 0.67
Extreme 0.6662
7.63
Manager TitleAgeSince
Chief Executive Officer 49 24/05/2017
Director of Finance/CFO 50 21/04/2024
Chief Tech/Sci/R&D Officer - 28/09/2025
Director TitleAgeSince
Director/Board Member 82 30/09/2003
Director/Board Member 82 30/11/2003
Chairman 69 08/12/2020
Date Insider Type Main position Quantity % Market Cap.
20/05/26 Free

Director

109,337 0.0354%
20/05/26 Free

Head of Human Resources

33,898 0.0110%
20/05/26 Other

Chairman

99,337 0.0322%
Change 5-day change 1-year change 3-year change Capi.($)
-0.25%-2.66%+1.77%-4.50% 1.25B
-7.17%-2.63%+49.59%+74.24% 55.98B
+0.24%-5.62%+54.73%+125.15% 53.69B
+0.80%-8.41%+3.57%+425.83% 23.29B
-0.09%-1.61%-18.68%-15.48% 23.15B
-5.95%-0.22%+35.96%-9.58% 20.58B
-1.14%-3.16%+32.88%-28.80% 17.76B
-5.16%-7.00%+177.56%+326.39% 16.09B
-6.91%+2.40%+36.86%+636.97% 15.93B
+0.43%-2.07%+24.79%+188.40% 14B
Average -2.50%-1.37%+39.90%+171.86% 24.17B
Weighted average by Cap. -2.89%-2.20%+43.37%+156.20%

Financials

2026 *2027 *
Net sales 463M 405M 373M 344M 649M 44.58B 663M 4.46B 1.76B 21.83B 1.74B 1.7B 75.16B 522M 456M 421M 388M 731M 50.23B 747M 5.03B 1.98B 24.6B 1.96B 1.92B 84.68B
Net income 72K 62.92K 58.06K 53.52K 101K 6.93M 103K 694K 273K 3.4M 270K 264K 11.69M 56.82M 49.66M 45.82M 42.24M 79.61M 5.47B 81.37M 548M 215M 2.68B 213M 209M 9.23B
Net Debt - -
Logo MannKind Corporation
MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Employees
592
Date Price Change Volume
17/07/26 US$4.030 -0.25% 3,497,048
16/07/26 US$4.040 -1.22% 3,299,606
15/07/26 US$4.090 +5.41% 5,611,449
14/07/26 US$3.880 -3.96% 4,649,492
13/07/26 US$4.040 -1.22% 4,043,863
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.040USD
Average target price
7.594USD
Spread / Average Target
+87.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNKD Stock